GLYC
GlycoMimetics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.13M
P/E Ratio
—
EPS
$-46.00
Beta
1.60
52W High
$18.40
52W Low
$0.15
50-Day MA
$22.49
200-Day MA
$24.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About GlycoMimetics Inc
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of new glucomimetic drugs to address unmet medical needs resulting from disease in the United States. The company is headquartered in Rockville, Maryland.
Fundamentals
| Revenue (TTM) | 10,000 |
| Gross Profit (TTM) | 10,000 |
| EBITDA | $-23.76M |
| Operating Margin | 0.00% |
| Return on Equity | -182.70% |
| Return on Assets | -74.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.23 |
| Price-to-Book | 300.17 |
| Price-to-Sales (TTM) | 1095.16 |
| EV/Revenue | 555.4 |
| EV/EBITDA | -0.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $64.53M |
| Float | 645,150 |
| % Insiders | 2.66% |
| % Institutions | 47.77% |
Data last updated: 4/8/2026